Bibliographic Details
| Title: |
Screening for Latent Tuberculosis Infection in People Living with HIV: TUBHIVIT Project, a Multicenter Italian Study |
| Authors: |
Luca Pipitò, Elena Delfina Ricci, Paolo Maggi, Giuseppe Vittorio De Socio, Giovanni Francesco Pellicano, Marcello Trizzino, Raffaella Rubino, Alessandra Lanzi, Lorenzo Crupi, Ilaria Capriglione, Nicola Squillace, Giuseppe Nunnari, Antonio Di Biagio, Paolo Bonfanti, Antonio Cascio |
| Source: |
Viruses, Vol 16, Iss 5, p 777 (2024) |
| Publisher Information: |
MDPI AG, 2024. |
| Publication Year: |
2024 |
| Collection: |
LCC:Microbiology |
| Subject Terms: |
tuberculosis, HIV, latent tuberculosis, TB, LTBI, Microbiology, QR1-502 |
| More Details: |
Background: The coexistence of HIV infection and latent tuberculosis infection (LTBI) presents a significant public health concern due to the increased risk of tuberculosis (TB) reactivation and progression to active disease. The multicenter observational cohort study, TUBHIVIT, conducted in Italy from 2017 to 2023, aimed to assess the prevalence of LTBI among people living with HIV (PLHIV) and their outcomes following LTBI screening and therapy initiation. Methods: We performed a prospective study in five referral centers for HIV care in Italy. PLHIV who consented Tto participate underwent QuantiFERON-TB Gold Plus and clinical, microbiological, and radiological assessments to exclude subclinical tuberculosis, as opportune. PLHIV diagnosed with LTBI who started chemoprophylaxis were followed until the end of therapy. Results: A total of 1105 PLHIV were screened for LTBI using the QuantiFERON-TB Gold Plus test, revealing a prevalence of 3.4% of positive results (38/1105). Non-Italy-born individuals exhibited a significantly higher likelihood of testing positive. Thirty-one were diagnosed with LTBI, 1 showed active subclinical TB, and 6 were lost to follow-up before discriminating between latent and active TB. Among the PLHIV diagnosed with LTBI, 83.9% (26/31) started chemoprophylaxis. Most individuals received 6–9 months of isoniazid-based therapy. Of the 26 PLHIV commencing chemoprophylaxis, 18 (69.2%) completed the therapy, while 3 discontinued it and 5 were still on treatment at the time of the analysis. Adverse events were observed in two cases, while in one case the patient refused to continue the treatment. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
1999-4915 |
| Relation: |
https://www.mdpi.com/1999-4915/16/5/777; https://doaj.org/toc/1999-4915 |
| DOI: |
10.3390/v16050777 |
| Access URL: |
https://doaj.org/article/f770217949174ba5b38105490e387dbd |
| Accession Number: |
edsdoj.f770217949174ba5b38105490e387dbd |
| Database: |
Directory of Open Access Journals |
|
Full text is not displayed to guests. |
Login for full access.
|
